Detalhe da pesquisa
1.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36335217
2.
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(2): 400, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36697966
3.
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study.
BMC Cancer
; 14: 166, 2014 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-24606768
4.
First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948505
5.
Phase II open-label study of sunitinib in patients with advanced breast cancer.
Breast Cancer Res Treat
; 136(3): 759-67, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23073758
6.
Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib.
J Transl Med
; 10: 165, 2012 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22897944
7.
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.
Breast Cancer Res Treat
; 121(1): 121-31, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20339913
8.
Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
Oncotarget
; 8(2): 2320-2328, 2017 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27906684
9.
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer.
Target Oncol
; 12(6): 775-785, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29067643
10.
Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology.
J Oncol Pract
; 12(8): e810-7, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27460496
11.
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Clin Pharmacol Drug Dev
; 4(2): 89-98, 2015 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27128213
12.
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014.
Clin Cancer Res
; 21(1): 60-7, 2015 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25231399
13.
Concordance and validation study of sentinel lymph node biopsy for breast cancer using subareolar injection of blue dye and technetium 99m sulfur colloid.
J Am Coll Surg
; 195(4): 467-75, 2002 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-12375751
14.
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Breast
; 22(5): 650-6, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23958375
15.
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
J Clin Oncol
; 31(23): 2870-8, 2013 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-23857972
16.
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer.
Breast
; 21(4): 507-13, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22336056
17.
An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer.
Breast
; 21(6): 716-23, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23022045
18.
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.
J Clin Oncol
; 30(9): 921-9, 2012 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22331954
19.
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.
Clin Breast Cancer
; 11(2): 82-92, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21569994
20.
When medical error becomes medical malpractice: the victims and the circumstances.
Arch Surg
; 138(4): 447-54, 2003 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-12686532